Tyrosine kinase inhibitors and mTOR inhibitors, as well as VEGF blockade have previously been used to treat metastatic RCC until the more recent development of immune checkpoint blockade (anti-PD1, anti-PDL1 and anti-CTLA4 antibodies), which has improved disease-free and overall survival (14). This evidence concerns the gene MTOR and renal cell carcinoma.